FABP4/5-IN-7

FABP4/5-IN-7 (Compound 2) (15-100 μM) binds to recombinant FABP4 with high affinity (K_d = 0.01 μM) and to recombinant FABP3 with lower affinity (K_d = 0.52 μM) in TdF assays^[1].
FABP4/5-IN-7 (10 μM) significantly inhibits basal lipolysis in fully differentiated 3T3-L1 adipocytes^[1].
FABP4/5-IN-7 (3-30 μM; 1 h pre-incubation, followed by 4 h incubation with isoproterenol) inhibits isoprenaline (HY-B0468)-stimulated lipolysis in fully differentiated 3T3-L1 adipocytes^[1].
FABP4/5-IN-7 (0.008-25 μM; 4 h) inhibits isoprenaline-stimulated lipolysis in primary human adipocytes, with an IC₅₀ of 22 μM^[1].
FABP4/5-IN-7 (24 h) inhibits basal MCP-1 release from THP-1 macrophage-like cells differentiated with PMA (HY-18739), with an IC₅₀ of 7.5 μM^[1].
FABP4/5-IN-7 (0.39-25 μM; 1 h pre-incubation, followed by 3 h incubation with LPS) significantly inhibits LPS (HY-D1056)-induced MCP-1 release from PMA-differentiated THP-1 macrophage-like cells at the concentration of 25 μM^[1].
FABP4/5-IN-7 (1-25 μM; overnight) inhibits MCP-1 release from primary human macrophages at a concentration of 25 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.